trending Market Intelligence /marketintelligence/en/news-insights/trending/EcJcUbldcL0QJX66H6igmA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Mallinckrodt drug improves kidney function in patients with rare liver disease

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Mallinckrodt drug improves kidney function in patients with rare liver disease

Mallinckrodt PLC said its treatment for a rare liver disease improved renal function and allowed patients to avoid dialysis during a late-stage study.

The phase 3 trial, named Confirm, compared terlipressin with placebo in 300 adults with hepatorenal syndrome type-1, or HRS-1. The rare disease has no approved therapies in the U.S and Canada.

HRS-1 is characterized by complications of liver disease that lead to kidney failure. More than 80% of the patients with HRS-1 die within three months, according to an Aug. 15 statement by the company.

Terlipressin was found to be effective in producing improvements in kidney function, providing short-term survival and allowing patients to avoid dialysis.

The U.K.-based pharmaceutical company said it plans to submit a new drug application for terlipressin with the U.S. Food and Drug Administration in early 2020.